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Abstract
Heart failure (HF) is often associated with pulmonary congestion, reduced
lung function, abnormal gas exchange, and dyspnea. We tested whether pul-
monary congestion is associated with expanded vascular beds or an actual
increase in extravascular lung water (EVLW) and how airway caliber is
affected in stable HF. Subsequently we assessed the influence of an inhaled
short acting beta agonist (SABA). Thirty-one HF (7F; age, 62  11 years; ht.
175  9 cm; wt. 91  17 kg; LVEF, 28  15%) and 29 controls (11F; age;
56  11 years; ht. 174  8 cm; wt. 77  14 kg) completed the study. Sub-
jects performed PFTs and a chest computed tomography (CT) scan before
and after SABA. CT measures of attenuation, skew, and kurtosis were
obtained from areas of lung tissue to assess EVLW. Airway luminal areas and
wall thicknesses were also measured. CT tissue density suggested increased
EVLW in HF without differences in the ratio of airway wall thickness to lumi-
nal area or luminal area to TLC (skew: 2.85  1.08 vs. 2.11  0.79, P < 0.01;
Kurtosis: 15.5  9.5 vs. 9.3  5.5 P < 0.01; control vs. HF). PFTs were
decreased in HF at baseline (% predicted FVC:101  15% vs. 83  18%,
P < 0.01;FEV1:103  15% vs. 82  19%, P < 0.01;FEF25–75: 118  36% vs.
86  36%, P < 0.01; control vs. HF). Airway luminal areas, but not CT mea-
sures, were correlated with PFTs at baseline. The SABA cleared EVLW and
decreased airway wall thickness but did not change luminal area. Patients with
HF had evidence of increased EVLW, but not an expanded bronchial circula-
tion. Airway caliber was maintained relative to controls, despite reductions in
lung volume and flow rates. SABA improved lung function, primarily by
reducing EVLW.
Introduction
The heart and lungs are intimately linked, with the dis-
ease pathophysiology of one organ system often influenc-
ing the other. In heart failure (HF) altered cardiac
hemodynamics lead to increased pressure within the lung
vasculature contributing to bronchial circulation engorge-
ment and/or a rise in extravascular lung water (EVLW)
via increased hydrostatic forces. Concurrently car-
diomegaly in HF patients competes with the lungs for
space within the thoracic cavity. Reflex-mediated changes
(e.g., due to cardiac stretch), biochemical modulators
(e.g., natriuretic peptides, angiotensin II), and alterations
in receptors (e.g., beta receptors) all potentially impact
airway and vascular function of the lungs. HF patients
demonstrate both restrictive and obstructive changes in
lung function, but there is substantial heterogeneity in the
impact of HF on the pulmonary system (Gehlbach and
Geppert 2004). This loss of pulmonary function generally
manifests as a decrease in forced vital capacity (FVC) and
forced expiratory volume in 1 sec (FEV1) as well as other
measures of maximal expiratory flow (Ravenscraft et al.
1993; Dimopoulou et al. 1998). These changes in lung
function have in turn been shown to contribute to
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abnormal gas exchange responses, both at rest and during
exercise, and subsequently contribute to the symptoms of
dyspnea and exercise intolerance, common in this patient
population (Johnson 2000).
While previous work has documented specific func-
tional changes to the lungs of HF patients, including
decreases in lung volumes and air flows, little work has
been done to understand the factors associated with pul-
monary congestion and how this in turn alters lung struc-
ture and function, especially in more stable disease
(Snyder et al. 2006b; Olson et al. 2007). While an
increase in EVLW may occur and be causative, swelling
of the bronchial circulation may also occur leading to
thickening of the airway walls and narrowing of the air-
way lumen causing reduced function (Cabanes et al.
1989; Ceridon et al. 2009). Previous work has suggested a
relationship between the airway luminal area of large to
medium-sized bronchioles and FEV1 in healthy individu-
als; however, the relationship between structural changes
and function in the HF population remains unclear
(Coxson et al. 2008).
An important modulator of airway caliber and lung
fluid regulation in HF patients is the beta 2 adrenergic
receptors (ADRB2). These receptors can be desensitized
with chronic elevations in catecholamines or chronic use
of a long-acting ADRB2 agonist as seen in asthmatics,
though it remains less clear if this occurs in HF (Eaton
et al. 2004; Gehlbach and Geppert 2004). In a previous
study from our laboratory, we demonstrated that HF
patients may have chronic overstimulation of the sympa-
thetic nervous system with evidence for decreased ADRB2
density resulting in altered airway function and reduced
lung fluid clearance (Snyder et al. 2006a,b). Stimulating
these receptors may lead to improved lymphatic dilation
and EVLW clearance as well as a mild influence on air-
way tone.
The purpose of this study was to determine if HF in
stable patients is associated with evidence of chronic con-
gestion and how this in turn might influence airway
structure and function in stable HF patients. In addition,
we sought to determine if an acutely inhaled ADRB2
agonist would reduce “congestion” and subsequently
improve the structure–function relationships. We hypoth-
esized that HF patients would demonstrate swollen air-
way walls, increased EVLW, or both leading to decreased
airway luminal area as compared to healthy controls,
particularly in airway generations further from the tra-
chea, leading to the reduction in lung function com-
monly observed in this population. We also hypothesized
acute inhalation of an ADRB2 agonist would reduce
swelling of the airway wall as well as EVLW and thus
increase airway luminal size and subsequently improve
airway function.
Methods
Participants
Seventy-one subjects were recruited for the study; how-
ever, the full dataset was not obtained on 11 subjects due
to scanner availability. Thirty-one subjects with a history
of HF and 29 age- and sex-matched controls completed
all portions of the study. Heart failure subjects had
greater than a 1 year history of disease, left ventricular
ejection (LVEF) fraction <40%, New York Heart Associa-
tion (NYHA) functional class of I, II, or III, and a body
mass index (BMI) less than 36 kg/m2. Subjects were cho-
sen with a range of clinical severity and either nonis-
chemic or ischemic etiology to observe a spectrum of
disease. Control subjects had no history of cardiovascular
or pulmonary disease and were current nonsmokers with
no or minimal smoking history (<15 pack years). The
study protocol was approved by Mayo Clinic institutional
review board and all subjects provided written informed
consent prior to participation.
Overview of experimental procedures
Experimental procedures were conducted on a single visit
day. A complete blood count was assessed to rule out ane-
mia. Spirometric measurements including FVC, FEV1, peak
expiratory flow (PEF), mean forced expiratory flow
between 25% and 75% of the FVC (FEF25–75) were assessed
according to standard techniques (Miller et al. 2005). Total
lung capacity (TLC) was calculated using helium dilution,
and a thoracic CT scan was obtained (see below details)
(Brown et al. 1998). Albuterol was administered through a
nebulizer at a dilution of 2.5 mg per 3 mL of saline over a
12–15 min period. Following albuterol administration,
pulmonary function, TLC, and a second CT scan were
obtained 45–60 min after nebulization.
CT scanning, tissue and air volumes, airway
segmentation
All CT scans were performed on the same scanner (GE
LiteSpeed Spiral CT Scanner, GE Healthcare) and obtained
using 2.5-mm-thick slices with 1.2 mm overlap and recon-
structed to 1.25-mm-thick slices with a 0.6 mm overlap.
An initial scout scan was performed to ensure capture of
the entire lung volume. The location of the scanner table,
field of view, and number images taken were recorded.
A mark was made on the subject to ensure alignment
between pre and postalbuterol scans. Subjects were
instructed to hold their breath at TLC during all scans.
Computed tomography quantitative analysis was carried
out using MATLAB (Mathworks, Inc, Natick, MA)
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software. The lung tissue was automatically segmented out
from the surrounding tissue using built-in algorithms. Pix-
els outside the range of 1000 to 0 HU and airways were
excluded from analysis. Values for the mean, skewness, and
kurtosis of the distributions were calculated from the seg-
mented areas (Best et al. 2003). Finally, the ratio of pixels
in the range greater than 500 HU was calculated as an
index of pulmonary congestion (Kato et al. 1996).
Scans were also submitted to image analysis software
(Vida Diagnostics, Coralville, IA) for automated analysis.
First, the software quantified the volumes of tissue (Vtis)
and air (Vair) within the lungs. The fraction of each voxel
that represents air and tissue was calculated from the lin-
ear attenuation of CT density from 1000 Hounsfield
units (Hu) to +55 Hu (Hoffman et al. 2006). The average
fraction of air and tissue of each voxel is then multiplied
by the total volume of the lung to calculate Vair and Vtis,
respectively.
The software used a novel segmentation algorithm that
has been described elsewhere to allow segmentation fur-
ther down the airway tree without “segmentation leak”
(Tschirren et al. 2005). The software then calculated the
area of the airway and thickness of the airway walls for
each generation. The algorithm successfully segmented at
least 6 generations from the trachea in all subjects and
thus additional generations were dropped from analysis.
Where specified, the airway areas were normalized to the
subject’s TLC, and the airway wall thickness was normal-
ized to the airway area at the same generation to account
for differences in body size and to show the relative
change with respect to lung volume changes.
Statistical analysis
All statistical analysis was carried out using SPSS (SPSS,
Chicago, IL). The independent sample t-test was used to
compare subject characteristics, pulmonary function, and
CT-derived data between HF and healthy populations.
The paired sample t-test was used to compare pre to
postalbuterol data. A Bonferroni correction was applied
for statistical tests across generations. Linear regression
and the Pearson correlation coefficient was used to assess
the relationship between pulmonary function and lung
structure data. All results are expressed as mean  SD
unless otherwise stated. The acceptable level of type I
error was defined as P < 0.05.
Results
Subject demographics
Seventy-one subjects were recruited for the study.
A postalbuterol CT scan could not be obtained in 11
(3 control, 8 HF) subjects due to scanner availability.
A complete dataset was obtained for 31 HF patients and
29 age-matched controls. Subject demographics are shown
in Table 1. The two groups were well matched for age
and height; however, average weight, BMI, and body sur-
face area (BSA) were higher in the HF group compared
to the control subjects (P < 0.01). HF patients included
those with nonischemic and ischemic etiologies with a
range of clinical severities.
Quantitative CT indices of congestion
The distribution of CT attenuation in the lung is shown
in Figure 1. Both groups had a similar mean, but the HF
group had a heavier right-side tail. Thus, the distribution
was wider and had a greater percentage of voxels greater
than 500 HU in the HF group. Quantitative CT indices
are shown in Table 2. The skew, kurtosis, and percentage
of voxels greater than 500 HU were significantly differ-
ent between the HF and control groups (P < 0.01) sug-
gesting greater levels of EVLW.
Airway wall thickness
Airway wall thickness decreased by approximately 10% in
each successive generation, but there was not a difference
between the groups at any generation (healthy, genera-
tions 1–6, mm: 2.53, 2.16, 1.71, 1.42, 1.22; HF, genera-
tions 1–6, mm: 2.62, 2.21, 2.03, 1.81, 1.48, 1.28;
P > 0.05). The airway wall thickness as a ratio of the area
Table 1. Participant characteristics in heart failure and control
subjects. Data are mean plus or minus standard deviation.
Control
X  SD
Heart failure
X  SD
N (Female) 29 (11) 31 (7)
Age, years 56.2  11.5 62.1  11.0
Height, cm 173.6  8.64 174.9  8.76
Weight, kg 77.4  14.4 91.4  17.7*
BMI, kg/m2 25.6  4.2 29.8  5.0*
BSA, m2 1.93  0.21 2.10  0.24*
LVEF, % – 28.2  15.3
Heart failure etiology
Dilated – 23
Ischemic – 15
Idiopathic – 1
NYHA functional class
I – 16
II – 14
III – 9
BMI, body mass index; BSA, body surface area; LVEF, left ventricu-
lar ejection fraction.
*P < 0.05 control versus heart failure.
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of that generation increased with increasing generation
(Fig. 2). There was no statistical difference between the
groups at any generation (P > 0.05).
Airway area
Airway area decreased by approximately half at each suc-
cessive generation and were not significantly different at
any generation between groups (healthy, generations 1–6,
mm: 245, 141, 83, 39, 19; HF, generations 1–6, mm: 267,
143, 83, 36, 19; P > 0.05). Airway area normalized to
TLC is shown in Figure 3. The normalized airway area
was significantly greater (P < 0.01) for all generations
except generations 3 and 4 in the HF group.
Pulmonary function
Pulmonary function characteristics are shown in Figure 4
for both groups. Percent predicted FVC, FEV1, forced
expiratory flow 25–75% (FEF25–75), and peak expiratory
flow (PEF) were significantly lower (P < 0.01) in the HF
group, while the FEV1/FVC ratio was not significantly dif-
ferent.
Structure–function relationships
Linear regression was performed to assess the relation-
ship between airway area and CT quantitative indices
and lung function. There were no correlations between
CT tissue histogram parameters and pulmonary function
at baseline. Pearson correlation coefficients for airway
area versus lung function are shown in Table 3. In the
control group, generation 2 was significantly correlated
with FEV1, FVC, FEF25–75, and PEF, and PEF was corre-
lated with all generations except generation 3. In the HF
group, generations 1, 2, and 4 were significantly corre-
lated with all measures, and PEF was correlated with all
generations.
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Figure 1. Histogram showing distribution of CT attenuation for the lungs of control (solid line) and heart failure (dashed line) groups at
baseline (black) and after albuterol administration (grey). Error bars are not shown for clarity.
Table 2. Baseline values and percent change after albuterol for quantitative CT indices.
Mean (HU) Skew Kurtosis FWHM (HU) Voxels > 500 HU (%)
Baseline
Control 827.4  50.9 2.86  1.07 15.52  9.5 94.5  38.5 1.05  0.83
HF 804.2  63.9 2.11  0.79* 9.34  5.5* 131.5  43.7* 1.83  1.93*
Mean (%) Skew (%) Kurtosis (%) FWHM (%) Voxels > 500 HU (%)
Change with Albuterol
Control 8.49  7.54# 54.7  66.9# 153.9  194.6# 27.1  22.1# 92.8  7.47#
HF 9.27  8.10# 86.7  116.1# 217.7  290.1# 29.9  18.9# 94.3  5.53#
FWHM, full width half max.
*P < 0.05 Heart failure (HF) mean versus control mean.
#P < 0.05 change from baseline mean different from zero.
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Effects of an ADRB2 agonist on lung
structure and function
After ADRB2 agonist administration, the CT attenuation
distributions for both groups shifted significantly to the left
and were narrower relative to baseline (Fig. 1). The mean,
skew, kurtosis, full width half max (FWHM), and percent-
age of voxels greater than 500 HU changed significantly
with similar changes between the groups (P < 0.01). Linear
regression for baseline values versus percent change of
mean attenuation, skew, kurtosis, FWHM, and percentage
of voxels greater than 500 HU showed a statistically sig-
nificant correlation for all values in both groups suggesting
greater clearance in those with more fluid at baseline
(Table 4). Agonist administration increased the absolute
size of the wall and decreased the fraction of the wall
relative to the area significantly (P < 0.05) in all genera-
tions for the HF group and generations 3 through 6 for the
control group (Fig. 5A). There was no statistical difference
between the groups after agonist administration. After
albuterol administration, neither the absolute (not shown)
nor the normalized airway areas changed for either group
or between groups (Fig. 5B). After albuterol administra-
tion (Fig. 5C), FEV1, FEV1/FVC, and FEF25–75 improved
significantly for the HF group (P < 0.05) and FEV1 and
FEF25–75 improved for the control group (P < 0.05). The
HF group improved more than the control group for FEV1
and FEF25–75 (P < 0.05). There was no difference after
albuterol for FVC, PEF, and TLC between groups. There
were no statistically significant correlations between
changes in pulmonary function and CT quantitative
indices or airway areas.
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Figure 2. Airway wall thickness normalized to airway radius for the control (solid diamond) and heart failure (open square) population at
baseline for airway generations 1 (trachea) to 6. Error bars are standard deviation.
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Figure 3. Airway luminal area normalized to TLC for the control (solid diamond) and heart failure (closed square) population at baseline for
airway generations 1 (trachea) to 6. Error bars are standard deviation. *P < 0.05 HF mean versus control mean.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2016 | Vol. 4 | Iss. 13 | e12867
Page 5
S. C. Chase et al. Lung Congestion in Heart Failure
Discussion
In this study, we examined measures of lung congestion,
airway structure and the relationship between airway
structure and lung function in HF patients and in control
subjects. In addition, we investigated if an acutely inhaled
ADRB2 agonist would help clear lung fluid and as a result
modulate airway structure–function relationships. We
found evidence for increased EVLW in the HF popula-
tion; however, no evidence was observed of an engorged
or swollen bronchial circulation as inferred by CT quan-
tification of airway walls. In addition, we found relatively
well preserved airway luminal areas in the first six genera-
tions of airways despite significantly reduced lung func-
tion. The inhaled ADRB2 agonist shifted the lung density
histogram away from water in both HF and control, had
no impact on airway wall thickness or airway luminal
areas, and improved lung function. Despite the parallel
changes in EVLW and lung function there was no clear
relationship between measures of air flow or lung vol-
umes and EVLW clearance. While we were not able to
detect a relationship, the increased fluid and decreased air
flows and volumes suggests that increased lung fluid may
be important in stable HF.
Extravascular lung water
Extravascular lung water (EVLW) is known to alter lung
mechanics and could contribute to the loss of function in
HF, but it is difficult to quantitatively measure in vivo
(Grossman et al. 1980; Esbenshade et al. 1982). Quantita-
tive CT indices, skew and kurtosis of the CT attenuation
distribution have previously been used to study interstitial
lung disease and pulmonary edema in HF. In patients
with idiopathic pulmonary fibrosis, disease progression is
associated with increased CT attenuation mean, decreased
skew, and decreased kurtosis and statistically significant
correlations between mean, kurtosis, and skew with FVC
and FEV1 (Hartley et al. 1994). In a previous study of HF
patients, histogram analysis showed a decreased CT
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Figure 4. Pulmonary function measurements for the control (solid diamond) and heart failure (open square) population at baseline. Error bars
are standard deviation. FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; FEF25–75, forced expiratory volume at 25–75% of
FVC; PEF, peak expiratory flow; TLC, total lung capacity. *P < 0.05 HF mean versus control mean.
Table 3. Pearson correlation coefficients (r) for airway area versus
pulmonary function at baseline.
Airway Generation
1 2 3 4 5 6
Control
FEV1 0.46 0.56* 0.32 0.31 0.31 0.29
FVC 0.39 0.53* 0.33 0.31 0.28 0.31
FEF25–75 0.53* 0.49* 0.24 0.25 0.40 0.30
PEF 0.59* 0.63* 0.25 0.40* 0.54* 0.47*
Heart failure
FEV1 0.55* 0.49* 0.40 0.51* 0.44* 0.28
FVC 0.54* 0.47* 0.38 0.47* 0.35 0.19
FEF25–75 0.50* 0.47* 0.31 0.46* 0.50* 0.40
PEF 0.64* 0.62* 0.58* 0.50* 0.54* 0.46*
*P < 0.05.
Table 4. Pearson correlation coefficients (r) for change in quanti-
tative CT indices at baseline versus change after albuterol for both
groups.
Mean Skew Kurt FWHM Voxels < 500 HU
Control 0.91* 0.71* 0.68* 0.67* 0.50*
HF 0.88* 0.80* 0.69* 0.60* 0.57*
*P < 0.05.
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attenuation mean and percent of pixels greater than
500 HU increased for subjects with severe pulmonary
congestion (Kato et al. 1996). In this study, we found
evidence for more fluid in the lung tissue in HF patients
compared to controls despite our patients being stable
and optimally managed (Table 2). The CT quantitative
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Figure 5. Percent change from baseline after ADRB2 agonist administration for airway wall thickness normalized to airway luminal area (A),
airway luminal area normalized to TLC (B), and lung function measures (C) for the control (solid diamond) and heart failure (closed square)
groups. Error bars are standard deviation. *P < 0.05 HF mean versus control mean, #P < 0.05 Control change from baseline mean different
from zero, $P < 0.05 HF change from baseline mean different from zero.
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indices measure both EVLW and small blood vessels;
however, it has been shown that small blood vessel vol-
ume is similar in HF patients versus controls, suggesting
that these indices are measuring primarily EVLW (Agos-
toni et al. 2006). Increased EVLW may decrease lung
compliance in HF as has been found in previous studies
(Frank et al. 1957). Our laboratory has previously found
increased elastic work of breathing during exercise, but
not at low levels of ventilation, in stable HF patients sug-
gesting decreased lung compliance (Cross et al. 2012).
While we found a mild increase in EVLW, we did not
find a clear relationship between the quantitative CT
indices of EVLW and measures of maximal air flow or
lung volumes. One explanation may be that the lung may
be able to tolerate a mild level of extravascular fluid accu-
mulation without a direct impact on lung function; how-
ever, preventing further increases in EVLW accumulation
may be important in preventing decompensation. EVLW
tends to flow toward the lymph system and avoid gas
exchange areas and the lymphatics in general may be
upregulated in the HF population due to a rapid shallow
breathing pattern and a rise in circulating catecholamines.
Airway wall thickness and luminal area
Numerous studies have attempted to understand the fac-
tors that contribute to loss of pulmonary function in HF.
Heart size has been found to be a significant factor
accounting for loss of lung volume (Olson et al. 2007).
We hypothesized that airway structure would also change
with the development of HF and increased EVLW. Specif-
ically, we hypothesized that HF (associated with increased
pulmonary wedge pressure) leading to vascular engorge-
ment of the bronchial circulation within the bronchiole
walls would cause thickening of the airway walls and a
subsequent decrease in luminal areas. Previous work has
suggested that the bronchial circulation is contained
within the airway wall, and its modulation can improve
exercise capacity in individuals with HF (Cabanes et al.
1989; King et al. 2002). Interestingly, we found that HF
patients maintained airway wall thickness and luminal
areas similar to control subjects, at least through six air-
way generations from the trachea (Figs 2 and 3).The lack
of change in the wall thickness suggests that the bronchial
circulation is not expanded in this population. Previous
studies in humans and animals after rapid fluid loading
have shown increased wall thicknesses and decreased
luminal areas, especially in smaller airways (Michel et al.
1986, 1987; Brown et al. 1995; King et al. 2002). How-
ever, one study found changes in respiratory bronchioles
and bronchioles, but not in bronchi after rapid fluid
loading in dogs, and a study in humans found changes in
airway wall thickness and luminal areas in only some
large airways after fluid loading healthy subjects (Michel
et al. 1986; Ceridon et al. 2010). In this study, we found
relatively mild levels of edema, which may not be enough
to cause significant swelling of the airway walls or nar-
rowing of the airway luminal area. Additionally, only gen-
erations 0 (trachea) through 6 (mid-sized bronchi) were
examined, which are relatively large, primarily cartilagi-
nous airways whose walls may be stiff enough to resist
engorgement with increased vascular volumes or com-
pression of the airways from increased interstitial fluid
(Voets and van Helvoort 2013).
Airway structure and lung function
Pulmonary function exhibited both restrictive and obstruc-
tive changes in HF patients in this study (Fig. 4). Previous
studies have shown approximately 20% reductions in FVC,
FEV1, and FEF25–75 with the development of HF (Snyder
et al. 2006b; Lizak et al. 2009). However, in both the
control and HF groups, the airway luminal area in at least
one generation was significantly related to each of the four
spirometry variables, FEV1, FVC, FEF25–75, and PEF at
baseline. It is possible that the airway generations most
responsible for modulating lung function with disease and
after ADRB2 agonist administration are located below the
resolution of CT scanning (beyond generation 6); this
is discussed in more depth below (see Limitations).
Furthermore, the location of the equal pressure point, or
the point of airway narrowing or collapse during a maxi-
mal expiration, is dependent on the resistance and luminal
area of the airways leading to limitations of flow through
that segment independent of driving pressure (Mead et al.
1967; Voets and van Helvoort 2013). This study suggests
that it is necessary to quantify smaller airways to properly
characterize the relationship between airway structure and
function.
Effect of an ADRB2 agonist
Albuterol, an ADRB2 agonist, has been shown to bron-
chodilate and clear EVLW through alveolar and lymphatic
mechanisms (Lauweryns and Baert 1977; Giembycz and
Raeburn 1991; Eaton et al. 2004). Lymphatic fluid clear-
ance has been shown to rapidly increase after pharmaco-
logical stimulation and in response to exercise in animal
models (Coates et al. 1984; Frank et al. 2000). Albuterol
effectively cleared fluid from both populations and cleared
more fluid in those subjects with more fluid at baseline
(Table 4). There was an effect of decreasing the size of
the airway wall relative to the luminal area but no effect
on the size of the airways for generations that could be
observed using CT imaging (Fig. 6A and B). Albuterol
administration improved air flows (FEV1 and FEF25–75),
2016 | Vol. 4 | Iss. 13 | e12867
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but not lung volumes, in both groups (Fig. 6C). This
improvement in FEF25–75 suggests that the effects of albu-
terol may be on smaller airways than those observed here.
We did not find statistically significant correlations
between changes in airway structure and lung function
from before to after ADBR2 administration. However,
these findings are similar to those found in study involv-
ing fluid loading healthy subjects. Fluid loading decreased
pulmonary function and changes were noted in airway
luminal area and wall thickness; however, relationships
were not found between the changes in airway structure
measurements of these large airways and lung function
measurements (Ceridon et al. 2010). While ADRB2 ago-
nists have been historically considered contraindicated in
HF, inhaled agonists have not been shown to increase
dysrhythmias (Maak et al. 2011).Therefore, an ADRB2
agonist may be an effective method of improving lung
function and clearing lung fluid in volume overloaded HF
patients.
Limitations
There are four major limitations of this study. First, the
difference in weight between the two groups may have
affected the differences in PFTs. However, one study
showed that increased body weight is associated with
increased spirometric parameters, suggesting that the dif-
ferences observed are not a result of body weight differ-
ences (Omori et al. 2014). Second, all CT measurements
were taken at TLC, which may not be representative of
functional lung volumes. A previous study in individuals
with asthma suggests that lung inflation to TLC can affect
the area of the large airways measured here (Brown et al.
2001). However, to limit radiation only one CT image
was taken per treatment condition. We chose to measure
at TLC to maximize the size of the airways and the ability
of the software to properly segment the airway structures
(Brown et al. 2001). Third, the resolution of the CT scan-
ning may not be sufficient to detect changes at smaller
airway generations. At generation 6, the diameter of the
airway is approximately 2 pixels, making the measure-
ment of airway area and luminal area susceptible to par-
tial volume effects. Nevertheless, this study has
characterized the more proximal airways that tend to be
cartilaginous, which are still an important determinant of
maximal air flow (Coxson et al. 2008). Finally, the sensi-
tivity of the automatic airway segmentation algorithm
may not properly segment all possible airways. While the
automatic segmentation algorithm has been well validated
on healthy individuals, it may occasionally miss airway
segments or, alternatively, segment nonairway structures,
leading to large standard deviations in the measurement
of airway area and wall thickness. In order to account for
these potential occurrences, we have been careful to visu-
ally validate the automatic segmentation to remove signif-
icant deviations from structures of interest.
Conclusion
The heart and lungs are intimately linked and during the
development and progression of the HF syndrome the
pulmonary system undergoes significant changes that in
turn contribute to the pathophysiology of the disease
through alterations in lung function, breathing pattern,
respiratory gas exchange, and ultimately symptomatology.
This study examined the structure–function relationships
of the pulmonary system in HF patients and the influence
of an acutely inhaled ADRB2 agonist; known to dilate air-
ways and stimulate extravascular lung fluid clearance. We
determined that EVLW was increased in clinically stable
HF patients. However, airway wall thicknesses and airway
luminal areas were maintained relative to healthy controls
in the large airways studied, despite significant reductions
in pulmonary function. An acutely nebulized ADRB2 ago-
nist caused significant clearance of EVLW, but did not
change airway wall thickness or luminal area in the large
generations, suggesting the importance of lung fluid in
stable HF patients, and the possibility of ADRB2 agonists
as a treatment in improving lung air flows and volumes
and clearing EVLW.
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